Combining dual-targeting approaches, like T-DM1 and neratinib—using mAbs to target the extracellular domain and TKIs for the intracellular segment—enhances the therapeutic impact, providing a more comprehensive strategy in managing HER2-positive BC (NCT05388149). The gene discussed is ERBB2; the disease is breast cancer.